NCT03666221

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

An Open,Multicenter,Phase II Trial of Intensity Modulated Radiation Therapy Combined With Concurrent Nimotuzumab in Patient With Recurrent Nasopharyngeal Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.

Detailed description

The clinical efficacy of Nimotuzumab combined with radiotherapy has been shown in advanced nasopharyngeal cancer, which was significantly higher than radiotherapy alone. The efficacy of radiotherapy combined with Nimotuzumab has not been confirmed in recurrent nasopharyngeal cancer.In this study, Phase II clinical trials were performed. The patients were treated with Nimotuzumab which were used concurrently with IMRT. The efficacy and toxicity will be assessed.

Conditions

• Recurrent Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Nimotuzumab	Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy

Timeline

• Start date: 2014-11-01
• Primary completion: 2020-04-01
• Completion: 2022-11-01
• First posted: 2018-09-11
• Last updated: 2018-09-11

Locations

1 site across 1 country: China